CA2555694C - Anti-epcam immunoglobulins - Google Patents

Anti-epcam immunoglobulins Download PDF

Info

Publication number
CA2555694C
CA2555694C CA2555694A CA2555694A CA2555694C CA 2555694 C CA2555694 C CA 2555694C CA 2555694 A CA2555694 A CA 2555694A CA 2555694 A CA2555694 A CA 2555694A CA 2555694 C CA2555694 C CA 2555694C
Authority
CA
Canada
Prior art keywords
cancer
epcam
immunoglobulin
serum
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2555694A
Other languages
English (en)
French (fr)
Other versions
CA2555694A1 (en
Inventor
Malte Peters
Mathias Locher
Nadja Prang
Cornelia Quadt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Research Munich GmbH
Original Assignee
Amgen Research Munich GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Research Munich GmbH filed Critical Amgen Research Munich GmbH
Publication of CA2555694A1 publication Critical patent/CA2555694A1/en
Application granted granted Critical
Publication of CA2555694C publication Critical patent/CA2555694C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA2555694A 2004-02-13 2005-02-09 Anti-epcam immunoglobulins Expired - Fee Related CA2555694C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/778,915 US20050180979A1 (en) 2004-02-13 2004-02-13 Anti-EpCAM immunoglobulins
US10/778,915 2004-02-13
PCT/EP2005/001307 WO2005080428A2 (en) 2004-02-13 2005-02-09 Anti-epcam immunoglobulins

Publications (2)

Publication Number Publication Date
CA2555694A1 CA2555694A1 (en) 2005-09-01
CA2555694C true CA2555694C (en) 2013-04-16

Family

ID=34838270

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2555694A Expired - Fee Related CA2555694C (en) 2004-02-13 2005-02-09 Anti-epcam immunoglobulins

Country Status (23)

Country Link
US (3) US20050180979A1 (cg-RX-API-DMAC10.html)
EP (2) EP1713830B1 (cg-RX-API-DMAC10.html)
JP (1) JP5220315B2 (cg-RX-API-DMAC10.html)
KR (1) KR101236224B1 (cg-RX-API-DMAC10.html)
CN (1) CN1976951B (cg-RX-API-DMAC10.html)
AT (1) ATE437186T1 (cg-RX-API-DMAC10.html)
AU (1) AU2005215874B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0507660A (cg-RX-API-DMAC10.html)
CA (1) CA2555694C (cg-RX-API-DMAC10.html)
DE (1) DE602005015544D1 (cg-RX-API-DMAC10.html)
DK (1) DK1713830T3 (cg-RX-API-DMAC10.html)
EA (1) EA011951B1 (cg-RX-API-DMAC10.html)
ES (1) ES2328159T3 (cg-RX-API-DMAC10.html)
IL (1) IL177069A (cg-RX-API-DMAC10.html)
MX (1) MXPA06008942A (cg-RX-API-DMAC10.html)
NO (1) NO339364B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ549125A (cg-RX-API-DMAC10.html)
PL (1) PL1713830T3 (cg-RX-API-DMAC10.html)
PT (1) PT1713830E (cg-RX-API-DMAC10.html)
SI (1) SI1713830T1 (cg-RX-API-DMAC10.html)
UA (1) UA87128C2 (cg-RX-API-DMAC10.html)
WO (1) WO2005080428A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200606083B (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004068110A2 (en) 2003-01-24 2004-08-12 University Of Utah Methods of predicting mortality risk by determining telomere length
WO2007008943A2 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
RU2434640C2 (ru) * 2006-02-09 2011-11-27 Микромет Аг Лечение метастатического рака молочной железы
EP1865001A1 (en) * 2006-06-08 2007-12-12 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Specific protease inhibitors and their use in cancer therapy
DK2041181T3 (da) * 2006-06-08 2011-08-29 Helmholtz Zentrum Muenchen Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi
CN101970497B (zh) * 2007-04-04 2017-05-10 希格马托制药工业公司 抗‑EpCAM抗体及其用途
ES2433718T3 (es) 2008-12-22 2013-12-12 University Of Utah Research Foundation PCR multiplex monocromática cuantitativa
US20120252022A1 (en) * 2009-09-21 2012-10-04 Paul Walfish Methods and compositions for the diagnosis and treatment of thyroid cancer
EP2819695B1 (en) * 2012-03-02 2018-06-27 Academia Sinica ANTI-EPITHELIAL CELL ADHESION MOLECULE (EpCAM) ANTIBODIES AND METHODS OF USE THEREOF
CN103387988B (zh) * 2012-09-24 2016-01-06 厦门大学 上皮细胞粘附分子的核酸适体EpCAM Ccut及其制备方法
JP6546158B2 (ja) 2013-05-22 2019-07-17 テロメア ダイアグノスティクス インコーポレイテッド 短いテロメアの存在量の測定
CN103275226B (zh) * 2013-06-09 2017-08-29 中国科学技术大学 特异性抗人上皮细胞粘附分子（EpCAM）的单克隆抗体的制备、鉴定及应用
US11046763B2 (en) * 2014-01-08 2021-06-29 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
WO2016108954A1 (en) 2014-12-30 2016-07-07 Telomere Diagnostics, Inc. Multiplex quantitative pcr
HUE054131T2 (hu) 2015-11-19 2021-08-30 Revitope Ltd Funkcionális ellenanyag-fragmens-komplementáció nemkívánatos sejtek elpusztítására szolgáló kétkomponensû rendszerben
CN110035768A (zh) 2016-07-26 2019-07-19 泰莎治疗私人有限公司 嵌合抗原受体
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
JP3876002B2 (ja) * 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US6855544B1 (en) * 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
BR0209177A (pt) * 2001-05-03 2004-10-05 Merck Patent Gmbh Anticorpo especìfico a tumor recombinante e uso do mesmo
US20030175268A1 (en) * 2002-01-11 2003-09-18 Saint-Remy Jean-Marie R. Method and pharmaceutical composition for preventing and/or treating systemic inflammatory response syndrome
WO2003099205A2 (en) * 2002-05-20 2003-12-04 Abgenix, Inc. Treatment of renal carcinoma using antibodies against the egfr

Also Published As

Publication number Publication date
NO339364B1 (no) 2016-12-05
NZ549125A (en) 2008-09-26
ZA200606083B (en) 2007-10-31
EP2107071A3 (en) 2009-12-30
EA200601386A1 (ru) 2007-06-29
JP2008500277A (ja) 2008-01-10
EP1713830B1 (en) 2009-07-22
US20070274982A1 (en) 2007-11-29
ES2328159T3 (es) 2009-11-10
PT1713830E (pt) 2009-10-19
EP2107071A2 (en) 2009-10-07
JP5220315B2 (ja) 2013-06-26
IL177069A0 (en) 2006-12-10
ATE437186T1 (de) 2009-08-15
US20120294873A1 (en) 2012-11-22
PL1713830T3 (pl) 2010-01-29
WO2005080428A3 (en) 2005-11-10
CA2555694A1 (en) 2005-09-01
IL177069A (en) 2010-11-30
US20050180979A1 (en) 2005-08-18
NO20064136L (no) 2006-11-07
HK1096103A1 (en) 2007-05-25
DK1713830T3 (da) 2009-10-12
MXPA06008942A (es) 2007-01-26
CN1976951B (zh) 2012-03-14
EA011951B1 (ru) 2009-06-30
UA87128C2 (ru) 2009-06-25
BRPI0507660A (pt) 2007-07-17
KR101236224B1 (ko) 2013-02-22
AU2005215874B2 (en) 2011-01-27
KR20070009988A (ko) 2007-01-19
WO2005080428A2 (en) 2005-09-01
EP1713830A2 (en) 2006-10-25
SI1713830T1 (sl) 2009-10-31
AU2005215874A1 (en) 2005-09-01
DE602005015544D1 (de) 2009-09-03
CN1976951A (zh) 2007-06-06

Similar Documents

Publication Publication Date Title
US20120294873A1 (en) ANTI-EpCAM IMMUNOGLOBULINS
CN116077647B (zh) 喹啉衍生物与抗体的药物组合
CN101365486B (zh) 使用抗egfr和抗her2抗体的联合治疗
WO1994022478A1 (en) PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST $i(NEU)
CN114044827B (zh) 低adcc/cdc功能性单抗及其制备方法与应用
CN113365650A (zh) 用il-7蛋白和免疫检查点抑制剂的组合治疗肿瘤的方法
US6733752B1 (en) Prevention of tumors with monoclonal antibodies against neu
CN110366562A (zh) 使用抗pd-l1抗体和抗雄激素治疗癌症的方法
EP2270053A1 (en) Humanized AXL antibodies
CN120842438A (zh) 一种以肽-n-糖苷酶为活性成分的融合蛋白及其制备方法和应用
JP2023554422A (ja) がんの治療のための多重特異性抗体
JP2025542297A (ja) 肺癌の組み合わせ療法
CN112672759B (zh) 抗程序性死亡配体-1(pd-l1)抗体的抗肿瘤用途
HK1096103B (en) Anti-epcam immunoglobulins
WO2023227115A1 (en) A method of treating solid tumor
US20240092934A1 (en) Assessment of ceacam1 expression on tumor infiltrating lymphocytes
EP4470562A1 (en) Anti-pd-l1 antibody-containing pharmaceutical composition used in combination with anti-vegf antibodies and paclitaxel
TW202432585A (zh) 癌症新輔助治療的組合物及方法
Garrett Peptide-based B-cell epitope vaccines targeting HER-2/neu
WO2022207727A1 (en) Antibody and use thereof for the treatment of cancer
KR20240038204A (ko) Pd-1에 특이적으로 결합하는 항체를 유효성분으로 포함하는 신경내분비 신생물의 예방 또는 치료용 약학 조성물
CN117545857A (zh) 用于癌症的治疗和诊断方法以及组合物
HK40056403A (en) Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20200210